Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Tumor-resident Microbiota-based Risk Model Predicts Neoadjuvant Therapy Response Of Locally Advanced Esophageal Squamous Cell Carcinoma Patients.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Tumor-resident Microbiota-based Risk Model Predicts Neoadjuvant Therapy Response Of Locally Advanced Esophageal Squamous Cell Carcinoma Patients.

Related Experiment Video

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

989

Tumor-Resident Microbiota-Based Risk Model Predicts Neoadjuvant Therapy Response of Locally Advanced Esophageal Squamous Cell Carcinoma Patients.

Hong Wu1,2,3,4, Qianshi Liu1,2,3,4, Jingpei Li5

  • 1Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610072, P. R. China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|September 13, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

A novel microbiota-based risk prediction (MRP) model identifies patients with esophageal squamous cell carcinoma (ESCC) who benefit from neoadjuvant therapy (NAT). This model, using specific gut bacteria, predicts treatment response and patient survival, offering new diagnostic biomarkers.

Keywords:
locally advanced esophageal squamous cell carcinomaneo‐adjuvant therapyrisk prediction modeltumor‐resident microbiota

More Related Videos

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids
10:43

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids

Published on: December 23, 2022

3.3K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

Related Experiment Videos

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

989
Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids
10:43

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids

Published on: December 23, 2022

3.3K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

Area of Science:

  • Oncology
  • Microbiome Research
  • Translational Medicine

Background:

  • Limited predictive biomarkers exist for neoadjuvant therapy (NAT) efficacy in esophageal squamous cell carcinoma (ESCC).
  • Intratumoral microbial composition is increasingly recognized for its role in cancer treatment response and prognosis.

Purpose of the Study:

  • To comprehensively profile intratumoral microbial composition for predicting NAT efficacy and prognosis in ESCC patients.
  • To develop and validate a microbiota-based risk prediction (MRP) model for ESCC patients undergoing NAT.

Main Methods:

  • Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis was used to identify key microbial genera (TM7x, Sphingobacterium, Prevotella).
  • A microbiota-based risk prediction (MRP) model was developed and validated across multiple centers.
  • The MRP-plus model incorporated tumor stage and size for enhanced prediction.

    • Main Results:

    • The MRP model demonstrated significant predictive accuracy for therapeutic responses in training, validation, and independent validation sets.
    • The MRP model accurately predicted disease-free survival and showed a trend towards predicting overall survival.
    • The MRP-plus model further improved the prediction of patient benefit from NAT.

    Conclusions:

    • The developed MRP and MRP-plus models serve as promising biomarkers for predicting NAT response and prognosis in ESCC.
    • These models offer accessible prognostic indicators at the time of diagnosis, aiding clinical decision-making.